N Plewig1, R Ofenloch1, T Mettang2, E Weisshaar1. 1. Department of Clinical Social Medicine, Occupational and Environmental Dermatology, Ruprecht Karls University, University Hospital Heidelberg, Heidelberg, Germany. 2. Department of Nephrology, DKD Helios Clinic, Wiesbaden, Germany.
Abstract
BACKGROUND: Chronic itch (CI) is a frequent symptom in hemodialysis (HD) patients. Previous studies demonstrated great impairments of general well-being and health-related quality of life (HRQOL) as well as a higher mortality in those suffering from CI. OBJECTIVE: The German Epidemiological Hemodialysis Itch Study (GEHIS) is a representative cohort of HD patients in Germany. All patients were followed up 4 years later. The current analyses present data on the course of CI in HD patients, its associated factors including comorbidities, laboratory values and HRQOL. METHODS: We assessed sociodemographic data, routine laboratory values, comorbidities, HRQOL (SF-12), depression and anxiety (HADS), sleep (duration and quality) and in those suffering from CI characteristics, intensity of CI and itch-related quality of life (ItchyQoL). Those with CI were offered a dermatological examination and CI was classified according to the IFSI classification. Patients were asked if they had consulted a physician about CI. RESULTS: Of the patients who had suffered from CI in 2013 (n = 234), 90.5% (212) patients could be followed up. About 36.3% (n = 85) had died, 9.8% (n = 23) had received a kidney transplant in the meantime. A total of 52 HD patients still suffered from CI, in 52 CI had stopped. Those patients still suffering from CI (n = 52) reported a higher mean itch intensity, lower ItchyQoL, higher levels of anxiety and a lower mean sleeping time in 2013. On the other hand, those who did not suffer from CI anymore showed a significant increase of HRQOL compared to 2013. There was no significant difference in dialysis characteristics and laboratory values except for albumin. Only a minority of patients in HD had consulted a dermatologist because of CI (29.9%). CONCLUSION: Our data demonstrate that CI is a persisting symptom in 50% of the HD patients and when it disappears HRQOL recovers. We confirm that CI is a disregarded symptom in HD patients.
BACKGROUND:Chronic itch (CI) is a frequent symptom in hemodialysis (HD) patients. Previous studies demonstrated great impairments of general well-being and health-related quality of life (HRQOL) as well as a higher mortality in those suffering from CI. OBJECTIVE: The German Epidemiological Hemodialysis Itch Study (GEHIS) is a representative cohort of HDpatients in Germany. All patients were followed up 4 years later. The current analyses present data on the course of CI in HDpatients, its associated factors including comorbidities, laboratory values and HRQOL. METHODS: We assessed sociodemographic data, routine laboratory values, comorbidities, HRQOL (SF-12), depression and anxiety (HADS), sleep (duration and quality) and in those suffering from CI characteristics, intensity of CI and itch-related quality of life (ItchyQoL). Those with CI were offered a dermatological examination and CI was classified according to the IFSI classification. Patients were asked if they had consulted a physician about CI. RESULTS: Of the patients who had suffered from CI in 2013 (n = 234), 90.5% (212) patients could be followed up. About 36.3% (n = 85) had died, 9.8% (n = 23) had received a kidney transplant in the meantime. A total of 52 HDpatients still suffered from CI, in 52 CI had stopped. Those patients still suffering from CI (n = 52) reported a higher mean itch intensity, lower ItchyQoL, higher levels of anxiety and a lower mean sleeping time in 2013. On the other hand, those who did not suffer from CI anymore showed a significant increase of HRQOL compared to 2013. There was no significant difference in dialysis characteristics and laboratory values except for albumin. Only a minority of patients in HD had consulted a dermatologist because of CI (29.9%). CONCLUSION: Our data demonstrate that CI is a persisting symptom in 50% of the HDpatients and when it disappears HRQOL recovers. We confirm that CI is a disregarded symptom in HDpatients.
Authors: Rebecca S Ahdoot; Kamyar Kalantar-Zadeh; James O Burton; Mark B Lockwood Journal: Curr Opin Nephrol Hypertens Date: 2022-01-01 Impact factor: 3.416
Authors: Esmee M van der Willik; Robin Lengton; Marc H Hemmelder; Ellen K Hoogeveen; Hans A J Bart; Frans J van Ittersum; Marc A G J Ten Dam; Willem Jan W Bos; Friedo W Dekker; Yvette Meuleman Journal: Nephrol Dial Transplant Date: 2022-08-22 Impact factor: 7.186
Authors: Daniel E Weiner; Marc G Vervloet; Sebastian Walpen; Thilo Schaufler; Catherine Munera; Frédérique Menzaghi; Warren Wen; Sarbani Bhaduri; Michael J Germain Journal: Kidney Med Date: 2022-08-24
Authors: Margaret K Vernon; Laura L Swett; Rebecca M Speck; Catherine Munera; Robert H Spencer; Warren Wen; Frédérique Menzaghi Journal: J Patient Rep Outcomes Date: 2021-12-24